The News

CoreValve names Daniel T. Lemaitre as Chief Executive Officer

30/04/2008

Irvine, Calif., April 30, 2008—CoreValve announced today that it has appointed Daniel T. Lemaitre as Chief Executive Officer, effective immediately.  He succeeds Jacques Séguin, M.D., Ph.D., co-founder of CoreValve, who will remain as Chairman of the Board.
 
Mr. Lemaitre has led Medtronic’s corporate strategic planning and corporate development functions since 2006 and also served as a senior member of Medtronic’s Policy, Management, Strategy, and Investment Committees. Previously, he spent 28 years in the investment community as a Chartered Financial Analyst focused on the health care industry.  He received his undergraduate degree in economics at Bethany College in West Virginia and his MBA from Bowling Green State University in Ohio, and serves on the board of Lawrence (Mass.) Academy.
“Dan Lemaitre is one of the savviest executives working in the medical device industry today. No doubt, his eagerness to join our company certainly bears strong witness to the remarkable opportunity ahead of CoreValve,” said Dr. Séguin.

“Dan has enormous credibility in the device industry, and therefore his appointment as CEO underscores CoreValve’s intent to strengthen its leadership position in the transcatheter valve replacement marketplace,” added Rob Michiels, COO of CoreValve. 

“With three device iterations in as many years and the smallest percutaneous system currently in the clinic, the CoreValve team has already demonstrated exceptional technical and operational abilities.  I look forward to being part of the team that will build on this foundation to create a major medical technology company,” said Mr. Lemaitre.

About CoreValve
CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving® System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving® System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery.

(Caution: the CoreValve ReValving® System will not be available in the USA for clinical trials or for sale until further notice.)